Explore the latest in amyotrophic lateral sclerosis, including recent advances in understanding the epidemiology and etiology of the disorder.
This Viewpoint provides recommendations for improvements to strengthen legal obligations and decrease ambiguity for the US Food and Drug Administration regarding their reliance on voluntary preapproval withdrawal pledges.
This JAMA Patient Page describes the neurological disorder amyotrophic lateral sclerosis and its symptoms, risk factors, diagnosis, and treatment options.
This narrative review discusses aspects of clinical trial design that may be important in discerning efficacy of treatments for amyotrophic lateral sclerosis (ALS).
This dual case-control and cohort study assesses for a characteristic pathological hallmark in the muscle tissues of patients with amyotrophic lateral sclerosis.
This randomized clinical trial showed that use of ultrahigh-dose methylcobalamin in Japanese patients in the early stages of amyotrophic lateral sclerosis with moderate progression can slow functional decline and had a good safety profile.
This multicenter cohort study uses real-world clinical data to compare the long-term safety and effectiveness of intravenous edaravone plus riluzole therapy vs propensity score–matched controls receiving riluzole therapy alone among patients with amyotrophic lateral sclerosis.
This cohort study evaluates the incidence of and mortality from amyotrophic lateral sclerosis (ALS) in National Football League (NFL) athletes from 1960 to 2019 and describes characteristics associated with ALS within this cohort.
This genetic association study identifies genetic variants associated with juvenile amyotrophic lateral sclerosis.
This Viewpoint describes the dearth of noninvasive ventilation for patients with amyotrophic lateral sclerosis in the US and proposes methods to increase access to this type of care.
This essay discusses the journey of a surgical oncologist as she navigates her father’s diagnosis of amyotrophic lateral sclerosis as a physician and daughter in the face of evolving health care value.
This randomized clinical trial examines the use of clinical neurophysiological metrics of excitability as pharmacodynamic biomarkers in individuals with amyotrophic lateral sclerosis.
This cohort study uses real-world data to assess patient characteristics and use as well as the safety and effectiveness of edaravone among patients with amyotrophic lateral sclerosis in the US Department of Veterans Affairs Health Care System.
Customize your JAMA Network experience by selecting one or more topics from the list below.